TLX101-PxNCT07931261
[18F]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain Metastases
StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Patient-Level Mean Dice Similarity Coefficient for Lesion Spatial Agreement Between Reduced-Dose and Full-Dose [18F]FET PET Images
Timeframe: From Day 1 through Day 2 (±1 day) follow-up
Sensitivity of [18F]FET PET for Distinguishing Tumor Progression From Treatment-Related Changes Compared With CSOT
Timeframe: From baseline Day 1 through CSOT determination (approximately 2-3 months).
Secondary (11)
Number of Participants With Adverse Events Following Administration of 740 MBq [18F]FET
Inter-Reader Agreement for [18F]FET PET Classification at the Optimized Dose
Lesion-Level Sensitivity of [18F]FET PET for Distinguishing Tumor Progression From Treatment-Related Changes
Sensitivity of [18F]FET PET Compared With Histopathologic Confirmation
Positive Predictive Value of [18F]FET PET for Tumor Progression Compared With CSOT
Show 6 moreShow less
Negative Predictive Value of [18F]FET PET for Tumor Progression Compared With CSOT
Maximum Standardized Uptake Value (SUVmax) of [18F]FET PET Lesions
Mean Standardized Uptake Value (SUVmean) of [18F]FET PET Lesions
Maximum Tumor-to-Brain Ratio (TBRmax) of [18F]FET PET Lesions
Mean Tumor-to-Brain Ratio (TBRmean) of [18F]FET PET Lesions
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) at the Optimized Dose
Arms and interventions
Arm Group Label: [18F]FET PET ImagingExperimental
Drugs: Floretyrosine F 18 ([18F]FET)